|
1
|
Lawrentschuk N, Davis ID, Bolton BM and
Scott AM: Functional imaging of renal cell carcinoma. Nat Rev Urol.
7:258–266. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kumar R, Shandai V, Shamim SA, Jeph S,
Singh H and Malhotra A: Role of FDG PET-CT in recurrent renal cell
carcinoma. Nucl Med Commun. 31:844–850. 2010.PubMed/NCBI
|
|
3
|
Minamimoto R, Nakaigawa N, Tateishi U, et
al: Evaluation of response to multikinase inhibitor in metastatic
renal cell carcinoma by FDG PET/contrast-enhanced CT. Clin Nucl
Med. 35:918–923. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Namura K, Minamimoto R, Yao M, Makiyama K,
et al: Impact of maximum standardized uptake value (SUVmax)
evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission
tomography/computed tomography (18F-FDG-PET/CT) on survival for
patients with advanced renal cell carcinoma: A preliminary report.
BMC Cancer. 10:6672010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang HY, Ding HJ, Chen JH, et al:
Meta-analysis of the diagnostic performance of [18F]FDG-PET and
PET/CT in renal cell carcinoma. Cancer Imaging. 12:464–474. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mitsudomi T, Hamajima N, Ogawa M and
Takahashi T: Prognostic significance of p53 alterations in patients
with non-small cell lung cancer: A meta-analysis. Clin Cancer Res.
6:4055–4063. 2000.PubMed/NCBI
|
|
7
|
Gerdes J, Schwab U, Lemke H and Stein H:
Production of a mouse monoclonal antibody reactive with a human
nuclear antigen associated with cell proliferation. Int J Cancer.
31:13–20. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rodins K, Cheale M, Coleman N and Fox SB:
Minichromosome maintenance protein 2 expression in normal kidney
and renal cell carcinomas: Relationship to tumor dormancy and
potential clinical utility. Clin Cancer Res. 8:1075–1081.
2002.PubMed/NCBI
|
|
9
|
Gianni L, Norton L, Wolmark N, Suter TM,
Bonadonna G and Hortobagyi GN: Role of anthracyclines in the
treatment of early breast cancer. J Clin Oncol. 27:4798–4808. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Albadine R, Wang W, Brownlee NA, et al:
Topoisomerase II alpha status in renal medullary carcinoma:
Immune-expression and gene copy alterations of a potential target
of therapy. J Urol. 182:735–740. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Murakami S, Saito H, Sakuma Y, Mizutani Y,
et al: Correlation of 18F-fluorodeoxyglucose uptake on positron
emission tomography with Ki-67 index and pathological invasive area
in lung adenocarcinomas 30 mm or less in size. Eur J Radiol.
75:e62–e66. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sobin LH, Gospodarowicz MK and Wittekind
CH: International Union Against Cancer: TNM Classification of
Malignant Tumors. 7th. Wiley-Blackwell; Baltimore, MD: pp. 253–257.
2009
|
|
13
|
Fuhrman SA, Lasky LC and Limas C:
Prognostic significance of morphologic parameters in renal cell
carcinoma. Am J Pathol. 6:655–663. 1982. View Article : Google Scholar
|
|
14
|
Groheux D, Martineau A, Vrigneaud JA, et
al: Effect of variation in relaxation parameter value on LOR-RAMLA
reconstruction of 18F-FDG PET studies. Nucl Med Commun. 30:926–933.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Noguchi M, Yao A, Harada M, et al:
Immunological evaluation of neoadjuvant peptide vaccination before
radical prostatectomy for patients with localized prostate cancer.
Prostate. 67:933–942. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dooms C, van Baardwijk A, Verbeken E, et
al: Association between 18F-fluoro-2-deoxy-d-glucose uptake values
and tumor vitality: Prognostic value of positron emission
tomography in early stage non-small cell lung cancer. J Thorac
Oncol. 4:822–828. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Folpe AL, Lyles RH, Sprouse JT, Conrad EU
III and Eary JF: (F-18) fluorodeoxyglucose positron emission
tomography as a predictor of pathologic grade and other prognostic
variables in bone and soft tissue sarcoma. Clin Cancer Res.
6:1279–1287. 2000.PubMed/NCBI
|
|
18
|
Watababe Y, Suefuji H, Hirose Y, et al:
18F-FDG uptake in primary gastric malignant lymphoma correlates
with glucose transporter-1 and histologic malignant potential. Int
J Hematol. 97:43–49. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim BS and Sung SH: Usefulness of 18F-FDG
uptake with clnicopathological and immunohistochemical prognostic
factors in breast cancer. Ann Nucl Med. 26:175–183. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nguyen XC, Lee WW, Chung JH, et al: FDG
uptake, glucose transporter type 1, and Ki-67 expressions in
non-small cell lung cancer: Correlations and prognostic values. Eur
J Radiol. 62:214–219. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dekel Y, Frede T, Kugel V, Neumann G,
Rassweiler J and Koren R: Human DNA topoisomerase II-alpha
expression in laparoscopically treated renal cell carcinoma. Oncol
Rep. 14:271–274. 2005.PubMed/NCBI
|
|
22
|
Kankuri M, Söderström K, Pelliniemi T,
Vahlberg T, Pyrhönen S and Salminen E: The association of
immunoreactive P53 and Ki-67 with T-stage, grade, occurrence of
metastases and survival in renal cell carcinoma. Anticancer Res.
26:3825–3833. 2006.PubMed/NCBI
|
|
23
|
Dudderidge TJ, Stoeber K, Loddo M, et al:
Mcm 2, Geminin, and Ki-67 define proliferative state and are
prognostic markers in renal cell carcinoma. Clin Cancer Res.
11:2510–2517. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cheng G, Torigian DA, Zhuang H and Alavi
A: When should we recommend use of dual time-point and delayed
time-point imaging techniques in FDG-PET? Eur J Nucl Med Mol
Imaging. 40:779–787. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Aide N, Cappele O, Bottet P, et al:
Efficiency of [18F] FDG PET in characterizing renal cancer and
detecting distant metastases: A comparison with CT. Eur J Nucl Med
Mol Imaging. 30:1236–1245. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wahl RL, Harney J, Hutchins G and Grossman
HB: Imaging of renal cancer using positron emission tomography with
2-deox-2-(18-F)-fluoro-D-glucose: Pilot animal and human studies. J
Urol. 146:1470–1474. 1991.PubMed/NCBI
|
|
27
|
Wong PK, Lee ST, Murone C, et al: In vivo
imaging of cellular proliferation in renal cell carcinoma using
18F-fluorothymidine PET. Asia Oceania J Nucl Med Biol. 2:3–11.
2014.
|
|
28
|
Higashi T, Saga T, Nakamoto Y, et al:
Relationship between retention index in dual phase 18F-FDG PET and
hexokinase-II and glucose transporter1 expression in pancreatic
cancer. J Nucl Med. 43:173–180. 2002.PubMed/NCBI
|
|
29
|
Zhao S, Kuge Y, Mochizuki T, et al:
Biologic correlates of intratumoral heterogeneity in 18F-FDG
distribution with regional expression of glucose transporters and
hexokinase-II in experimental tumor. J Nucl Med. 46:675–682.
2005.PubMed/NCBI
|
|
30
|
Waki A, Kato H, Yano R, et al: The
importance of glucose transporter activity as the rate-limiting
step of 2-deoxygluoce uptake in tumors cells in vitro. Nucl Med
Biol. 25:593–597. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ozülker T, Ozülkar F, Ozbek E and Ozpaçaci
T: A prospective diagnostic accuracy study of F-18
fluorodeoxyglucose-positron emission tomography/computed tomography
in the evaluation of indeterminate renal masses. Nucl Med Commun.
32:265–272. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ho CL, Chen S, Ho KM, et al: Dual-tracer
PET/CT in renal angiomyolipoma and subtypes of renal cell
carcinoma. Clin Nucl Med. 37:1075–1082. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chang CC, Cho SF, Chen YW, Tu HP, Lin CY
and Chang CS: SUV on dual-phase FDG PET/CT correlates with the
Ki-67 proliferation index in patients with newly diagnosed
non-Hodgkin lymphoma. Clin Nucl Med. 37:e189–e195. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
García Vicente AM, Castrejón ÁS, Relea
Calatayud F, Muñoz AP, León Martín AA, López-Muñiz IC, et al:
18F-FDG retention index and biologic prognostic parameters in
breast cancer. Clin Nucl Med. 37:460–466. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ferda J, Ferdova E, Hora M, Hes O, Finek
J, Topolcan O and Kreuzberg B: 18F-FDG-PET/CT in potentially
advanced renal cell carcinoma: A role in treatment decisions and
prognosis estimation. Anticancer Res. 33:2665–2672. 2013.PubMed/NCBI
|
